FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2136324712> ?p ?o ?g. }

• W2136324712 endingPage "32" @default.
• W2136324712 startingPage "24" @default.
• W2136324712 abstract "Background Several clinical studies have demonstrated that body weight increases after treatment with thiazolidinediones (TZDs). Prior studies have demonstrated an increase in insulin-stimulated lipid storage in adipose tissue. Some, but not all, studies demonstrate reductions in visceral adipose tissue. Changes in body weight are the result of changes in energy intake, energy expenditure, or both. Objectives Based on these findings, the primary aim of this study was to evaluate the effect of TZDs on visceral, subcutaneous, and total body fat. Secondary aims were to determine the effects of pioglitazone on (a) energy expenditure, (b) hunger and satiety, (c) blood lipids, and (d) the role of insulinemia/sulfonylurea usage on weight gain in patients with type 2 diabetes. Subjects and Methods We performed a randomized, double-blind, placebo-controlled trial in 48 men and women with type 2 diabetes who had not previously received treatment with TZDs. Patients were treated for 24 weeks with 45 mg/d of pioglitazone or a matching placebo. Body composition was measured by dual-energy x-ray absorptiometry. Visceral and subcutaneous fat were measured by computed tomography. Resting metabolic rate and thermogenic response to a test meal were measured by indirect calorimetry before and after a standardized meal. Hunger and satiety were measured with visual analog scales before and after the same test meal. Blood was collected for the measurement of fasting glucose and insulin levels, hemoglobin A1c levels, and lipid content. Results Pioglitazone treatment resulted in a decrease in hemoglobin A1c level by 0.96 ± 1.1% vs 0.11 ± 0.8% in the placebo group (P < .005). Body weight and fat increased steadily in the patients treated with pioglitazone during the 6 months of the study (+3.9 ± 3.1 kg at 6 months in pioglitazone-treated patients vs −0.8 ± 3.4 kg in the placebo-treated patients). Subcutaneous fat in the trunk, arms, and legs were all increased in the pioglitazone-treated group. Visceral fat did not change significantly in either group. Neither resting metabolic rate nor the thermogenic responses to a meal were altered by pioglitazone. Subjective measures of hunger (visual analog scale) did not change with pioglitazone treatment. Triglycerides fell in the pioglitazone-treated group (−58.5 ± 124 mg/dL, P < .003). Neither the prior use of sulfonylureas nor the level of insulinemia before treatment was a predictor of weight or fat change. Conclusion Pioglitazone increased subcutaneous body fat, but not visceral fat. There was no measurable effect on energy expenditure or hunger/satiety. In contrast to the placebo-treated patient with diabetes, weight gain occurs in the face of falling hemoglobin A1c and triglyceride levels." @default.
• W2136324712 created "2016-06-24" @default.
• W2136324712 creator A5001163309 @default.
• W2136324712 creator A5004522987 @default.
• W2136324712 creator A5047527237 @default.
• W2136324712 creator A5058441976 @default.
• W2136324712 creator A5072986611 @default.
• W2136324712 creator A5076120453 @default.
• W2136324712 date "2005-01-01" @default.
• W2136324712 modified "2023-09-29" @default.
• W2136324712 title "Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial" @default.
• W2136324712 cites W1876586283 @default.
• W2136324712 cites W1964716328 @default.
• W2136324712 cites W1969060340 @default.
• W2136324712 cites W1987692887 @default.
• W2136324712 cites W1999236387 @default.
• W2136324712 cites W2019280401 @default.
• W2136324712 cites W2020949125 @default.
• W2136324712 cites W2031773477 @default.
• W2136324712 cites W2046833545 @default.
• W2136324712 cites W2047591801 @default.
• W2136324712 cites W2070242218 @default.
• W2136324712 cites W2085608095 @default.
• W2136324712 cites W2087588721 @default.
• W2136324712 cites W2100514340 @default.
• W2136324712 cites W2107207934 @default.
• W2136324712 cites W2125090169 @default.
• W2136324712 cites W2131652042 @default.
• W2136324712 cites W2143808884 @default.
• W2136324712 cites W4230284962 @default.
• W2136324712 cites W4239995626 @default.
• W2136324712 cites W4243394305 @default.
• W2136324712 cites W4248394285 @default.
• W2136324712 doi "https://doi.org/10.1016/j.metabol.2004.07.008" @default.
• W2136324712 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15562376" @default.
• W2136324712 hasPublicationYear "2005" @default.
• W2136324712 type Work @default.
• W2136324712 sameAs 2136324712 @default.
• W2136324712 citedByCount "151" @default.
• W2136324712 countsByYear W21363247122012 @default.
• W2136324712 countsByYear W21363247122013 @default.
• W2136324712 countsByYear W21363247122014 @default.
• W2136324712 countsByYear W21363247122015 @default.
• W2136324712 countsByYear W21363247122016 @default.
• W2136324712 countsByYear W21363247122017 @default.
• W2136324712 countsByYear W21363247122018 @default.
• W2136324712 countsByYear W21363247122019 @default.
• W2136324712 countsByYear W21363247122020 @default.
• W2136324712 countsByYear W21363247122021 @default.
• W2136324712 countsByYear W21363247122022 @default.
• W2136324712 countsByYear W21363247122023 @default.
• W2136324712 crossrefType "journal-article" @default.
• W2136324712 hasAuthorship W2136324712A5001163309 @default.
• W2136324712 hasAuthorship W2136324712A5004522987 @default.
• W2136324712 hasAuthorship W2136324712A5047527237 @default.
• W2136324712 hasAuthorship W2136324712A5058441976 @default.
• W2136324712 hasAuthorship W2136324712A5072986611 @default.
• W2136324712 hasAuthorship W2136324712A5076120453 @default.
• W2136324712 hasConcept C126322002 @default.
• W2136324712 hasConcept C134018914 @default.
• W2136324712 hasConcept C142724271 @default.
• W2136324712 hasConcept C171089720 @default.
• W2136324712 hasConcept C204787440 @default.
• W2136324712 hasConcept C27081682 @default.
• W2136324712 hasConcept C2777180221 @default.
• W2136324712 hasConcept C2778384471 @default.
• W2136324712 hasConcept C2779306644 @default.
• W2136324712 hasConcept C555293320 @default.
• W2136324712 hasConcept C71924100 @default.
• W2136324712 hasConceptScore W2136324712C126322002 @default.
• W2136324712 hasConceptScore W2136324712C134018914 @default.
• W2136324712 hasConceptScore W2136324712C142724271 @default.
• W2136324712 hasConceptScore W2136324712C171089720 @default.
• W2136324712 hasConceptScore W2136324712C204787440 @default.
• W2136324712 hasConceptScore W2136324712C27081682 @default.
• W2136324712 hasConceptScore W2136324712C2777180221 @default.
• W2136324712 hasConceptScore W2136324712C2778384471 @default.
• W2136324712 hasConceptScore W2136324712C2779306644 @default.
• W2136324712 hasConceptScore W2136324712C555293320 @default.
• W2136324712 hasConceptScore W2136324712C71924100 @default.
• W2136324712 hasIssue "1" @default.
• W2136324712 hasLocation W21363247121 @default.
• W2136324712 hasLocation W21363247122 @default.
• W2136324712 hasOpenAccess W2136324712 @default.
• W2136324712 hasPrimaryLocation W21363247121 @default.
• W2136324712 hasRelatedWork W1957106181 @default.
• W2136324712 hasRelatedWork W2033522292 @default.
• W2136324712 hasRelatedWork W2042938358 @default.
• W2136324712 hasRelatedWork W2044897248 @default.
• W2136324712 hasRelatedWork W2056633665 @default.
• W2136324712 hasRelatedWork W2081564223 @default.
• W2136324712 hasRelatedWork W2121496639 @default.
• W2136324712 hasRelatedWork W2159949415 @default.
• W2136324712 hasRelatedWork W4240196000 @default.
• W2136324712 hasRelatedWork W8919293 @default.
• W2136324712 hasVolume "54" @default.
• W2136324712 isParatext "false" @default.
• W2136324712 isRetracted "false" @default.

• next